Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study
Immuntherapie versus Chemo-Immuntherapie als First-Line-Behandlung bei metastasiertem nicht-kleinzelligem Lungenkarzinom mit PD-L1 TPS ≥ 50 %: eine realweltliche retrospektive Studie
Journal of Clinical Medicine · 21.03.2026 · 15 (6) · 2406
DOI: 10.3390/jcm15062406 ↗Auf einen Blick
Bei 65 Patient:innen mit metastasiertem NSCLC und PD-L1 TPS ≥ 50 % zeigten sich zwischen Pembrolizumab-Monotherapie und Chemo-Immuntherapie keine signifikanten Unterschiede bei PFS oder OS. Ein TPS ≥ 90 % war mit besseren Überlebensdaten assoziiert.
Fragestellung
Unterscheidet sich bei metastasiertem NSCLC mit PD-L1 TPS ≥ 50 % das Überleben unter Pembrolizumab-Monotherapie gegenüber Pembrolizumab plus platinbasierter Chemotherapie?
Methode
Retrospektive Auswertung von Patient:innen mit metastasiertem NSCLC und PD-L1 TPS ≥ 50 %; Erstlinientherapie mit Pembrolizumab-Monotherapie oder Pembrolizumab plus platinbasierter Chemotherapie; Zentrum in Istanbul; Juli 2017 bis Dezember 2024.
Ergebnisse
65 Patient:innen: 36 mit Pembrolizumab plus Chemotherapie, 29 mit Pembrolizumab-Monotherapie. Medianes PFS 24,2 Monate (95 %-KI 6,5–33,0), medianes OS 34,6 Monate (95 %-KI 6,5–62,7). Keine signifikanten Unterschiede zwischen den Strategien.
Schlussfolgerung der Autor:innen
In dieser realweltlichen Kohorte war die PD-L1-Expression, besonders TPS ≥ 90 %, eng mit den Überlebensoutcomes verbunden. Zwischen den Behandlungsstrategien im Gesamtkollektiv zeigten sich keine Überlebensunterschiede.
Kernaussagen
- Kein signifikanter PFS- oder OS-Unterschied zwischen den Strategien
- TPS ≥ 90 % blieb ein unabhängiger Prognosefaktor für OS
- Hypertonie war ein unabhängiger negativer Prognosefaktor für PFS
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 21.03.2026. Verfasst von Maral Martin Mildanoglu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Istanbul Medipol University, 34214 Istanbul, Turkey. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Immune checkpoint inhibitors (ICIs) have become the standard first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) with high programmed death-ligand 1 (PD-L1) expression. However, the optimal selection between immunotherapy monotherapy and chemo-immunotherapy in patients with a PD-L1 tumor proportion score (TPS) ≥ 50% remains uncertain in routine clinical practice.
Methods
We retrospectively reviewed patients with metastatic NSCLC and a PD-L1 TPS ≥ 50% who initiated first-line treatment with pembrolizumab monotherapy or pembrolizumab combined with platinum-based chemotherapy at the Istanbul Medipol University Department of Medical Oncology between July 2017 and December 2024. Survival outcomes, including progression-free survival (PFS) and overall survival (OS), were evaluated and compared according to PD-L1 expression levels and treatment strategy. Prognostic factors associated with survival outcomes were also explored.
Results
A total of 65 patients were included, of whom 36 received pembrolizumab plus chemotherapy and 29 received pembrolizumab monotherapy. The estimated median PFS and OS for the entire cohort were 24.2 months (95% CI, 6.5–33.0) and 34.6 months (95% CI, 6.5–62.7), respectively. Patients with very high PD-L1 expression (TPS ≥ 90%) experienced significantly longer survival outcomes compared with those with a TPS of 50–89%, and a PD-L1 TPS ≥ 90% remained an independent prognostic factor for OS. When treatment strategies were compared across the entire cohort, no statistically significant differences in PFS or OS were observed between immunotherapy monotherapy and chemo-immunotherapy. Hypertension was identified as an independent negative prognostic factor for PFS. In patients with a PD-L1 TPS ≥ 90%, survival outcomes numerically favored pembrolizumab monotherapy, although this difference did not reach statistical significance.
Conclusions
In this real-world cohort of patients with PD-L1 high metastatic NSCLC, PD-L1 expression, particularly very high TPS levels, was strongly associated with survival outcomes. While no survival differences were observed between treatment strategies in the overall population, pembrolizumab monotherapy may represent an appropriate first-line option in selected patients with a PD-L1 TPS ≥ 90%. Larger prospective studies are warranted to refine treatment selection in this setting.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology, Istanbul Medipol University, 34214 Istanbul, Turkey.
ORCID-Profile: Maral Martin Mildanoglu, Mehmet Haluk Yucel, Ebru Engin Delipoyraz, Erdem Sunger, Sena Fidan, Harun Muglu, Jamshid Hamdard, Burcin Cakan Demirel, Yasin Kutlu, Ozgur Acikgoz, Ahmet Bilici
Zitieren
APA
Mildanoglu, M. M., Yucel, M. H., Engin Delipoyraz, E., Sunger, E., Ozcelik, H., Fidan, S., Terzioglu, C., Muglu, H., Hamdard, J., Cakan Demirel, B., Kutlu, Y., Acikgoz, O., Seker, M., & Bilici, A. (2026). Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study. Journal of Clinical Medicine, 15(6), 2406. https://doi.org/10.3390/jcm15062406
Vancouver
Mildanoglu MM, Yucel MH, Engin Delipoyraz E, Sunger E, Ozcelik H, Fidan S, et al. Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study. Journal of Clinical Medicine. 2026;15(6):2406. doi:10.3390/jcm15062406
BibTeX
@article{Mildanoglu2026,
author = {Mildanoglu, Maral Martin and Yucel, Mehmet Haluk and Engin Delipoyraz, Ebru and Sunger, Erdem and Ozcelik, Hakan and Fidan, Sena and Terzioglu, Cihat and Muglu, Harun and Hamdard, Jamshid and Cakan Demirel, Burcin and Kutlu, Yasin and Acikgoz, Ozgur and Seker, Mesut and Bilici, Ahmet},
title = {Immunotherapy Versus Chemo-Immunotherapy as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with PD-L1 TPS ≥ 50%: A Real-World Retrospective Study},
journal = {Journal of Clinical Medicine},
year = {2026},
volume = {15},
number = {6},
pages = {2406},
doi = {10.3390/jcm15062406}
}
EUVIMED